,
1 min read
China remains one of the world’s most strategic pharmaceutical markets, and understanding the China MAH System is essential for successful product registration and commercialization. Introduced to modernize regulatory oversight, the Marketing Authorization Holder (MAH) system separates product authorization from manufacturing responsibility, creating greater flexibility for domestic and foreign pharmaceutical companies.
What Is the China MAH System?
The China Marketing Authorization Holder (MAH) system allows an entity other than the manufacturer to hold the marketing authorization for a medicinal product. This means companies can own and market a drug product while outsourcing manufacturing to qualified facilities.
The system was first piloted in 2016 and later formalized under China’s revised Drug Administration Law, becoming a core pathway for China's drug registration and market entry.
Why the China MAH System Matters
The MAH framework continues to reshape China's pharmaceutical regulations by enabling:
- Greater flexibility for global innovators entering China
- Outsourced manufacturing through qualified CMOs/CDMOs
- Faster commercialization strategies
- Improved accountability for product quality, safety, and efficacy
- Stronger lifecycle management after approval
For biotech companies, foreign manufacturers, and R&D-focused organizations, the MAH model reduces the need to own local manufacturing facilities.
Key Responsibilities of an MAH in China
Holding authorization also means holding responsibility. MAHs are expected to maintain:
1. Product Quality Oversight
Ensure GMP-compliant manufacturing, supplier qualification, and batch release control.
2. Pharmacovigilance & Safety Reporting
Maintain adverse event reporting systems and post-market surveillance processes.
3. Change Control & Lifecycle Management
Manage variations, renewals, labeling updates, and manufacturing site changes.
4. Product Recall & Traceability
Implement product recall procedures and full batch traceability systems.
5. Regulatory Compliance with NMPA
Respond to inspections, regulatory queries, and ongoing documentation requirements.
Common Challenges for Foreign Companies
Despite the advantages, foreign applicants may face:
- Need for local legal representation
- Complex dossier preparation requirements
- China-specific technical expectations
- Ongoing post-approval compliance obligations
- Evolving NMPA regulatory requirements
This makes local regulatory expertise critical for long-term success.
How Freyr Solutions Can Help
Freyr Solutions supports pharmaceutical companies with:
- China MAH strategy and regulatory pathway assessment
- NMPA registration planning and execution
- eCTD dossier publishing and submissions
- Local representation support
- Pharmacovigilance and post-market compliance
- Variations, renewals, and lifecycle management
Final Thoughts
The China MAH System offers a more flexible route to pharmaceutical market access, but success depends on meeting both pre-approval and post-approval obligations. Companies that understand MAH responsibilities early can reduce delays, lower risk, and accelerate approvals.
Planning to enter the China pharmaceutical market? Connect with Freyr Solutions today and speak with our China regulatory experts.
